Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis
详细信息 查看全文
- 作者：Louise Rath ; Nirosen Vijiaratnam and Olga Skibina
- 刊名：Internal Medicine Journal
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：47
- 期：2
- 页码：194-199
- 全文大小：353K
- ISSN：1445-5994
文摘
Natalizumab, a monoclonal antibody directed against α4 integrin, is a highly efficacious treatment commonly used in relapsing remitting multiple sclerosis. Natalizumab is associated with the potentially fatal, rare, demyelinating, opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Prognosis and disability from PML are determined by early diagnosis.